Open AccessLong-Term Efficacy and Safety of the HIV Integrase Inhibitor Raltegravir in Patients With Limited Treatment Options in a Phase II Study
Author(s) -
José M. Gatell,
Christine Katlama,
Beatriz Grinsztejn,
Joseph J. Eron,
Adriano Lazzarin,
D. Vittecoq,
Charles J. Gonzalez,
Robert M. Danovich,
Hong Wan,
Jing Zhao,
Anne R. Meibohm,
Kim M. Strohmaier,
Charlotte Harvey,
Robin Isaacs,
Bach Nguyen
Publication year - 2010
Publication title -
journal of acquired immune deficiency syndromes
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.162
H-Index - 157
eISSN - 1944-7884
pISSN - 1525-4135
DOI - 10.1097/qai.0b013e3181c9c967
Subject(s) - raltegravir , integrase inhibitor , integrase , medicine , virology , human immunodeficiency virus (hiv) , term (time) , pharmacology , antiretroviral therapy , viral load , physics , quantum mechanics
Raltegravir in combination therapy has demonstrated potent suppression of HIV-1 with a favorable safety profile. This report provides 96-week efficacy and safety data from Protocol 005, a Phase II study.